Background: In the past 20 years, various central venous catheters have been used more and more in dialysis treatment, and the use of catheters as vascular access in various acute and chronic renal failures has been increasingly accepted by clinicians and patients. However, the widespread use of central venous catheters inevitably increases the risk of various complications such as infection, catheter insufficiency, and deep venous obstruction, which both threaten the quality of survival and life safety of dialysis patients and consume a lot of medical resources. Objective: To investigate the occurrence, lesion characteristics and risk factors of catheter-related complications in hemodialysis patients with temporary central venous indwelling catheters through a retrospective clinical case study. Methods: 261 patients with temporary central venous catheters in Guangzhou Red Cross Hospital from January 2002 to July 2008 were used as the study subjects: 1. To collect clinical data and biochemical indexes, and analyze the occurrence of hemodialysis catheter-related complications, lesion characteristics and risk factors. 2. To observe the treatment measures for various complications. Results: 1. Among 261 patients, the average age was (64.14±16.68) years; 312 catheters were placed, and the subclavian, femoral and internal jugular veins were placed 201, 68 and 43 times, respectively, with the average retention time of (18.13±16.45), (15.68±19.81) and (16.81±11.84) days, and the total retention time of 3645, 1066, and 723 days. Dialysis catheter-associated infection (HCRI), catheter insufficiency (CD), and deep venous obstruction syndrome occurred 40, 49, and 13 times, respectively, with incidence rates of 12.8% (7.36 times/catheter day), 15.7%, and 5.3%, respectively. 2, HCRI was correlated with placement site, retention time, age, and diabetes mellitus, and its ORs were 1.599 (1.035-2.468), 1.022 (0.996-1.040), 1.026 (0.998-1.055), and 2.501 (1.153-5.426), respectively; subclavian, femoral, and internal jugular vein placement The incidence of HCRI was 9.0% (4.94 times/catheter day), 22.1% (14.07 times/catheter day), and 16.3% (9.68 times/catheter day), respectively, with a significant difference at P < 0.05; the incidence of HCRI was 7.5% and 17.4% within 2 weeks and >2 weeks of placement time, respectively, with a significant difference at P < 0.05. The incidence of CD was 11.2% and 19.3% within 2 weeks and more than 2 weeks, respectively, and the difference was statistically significant; the effect of placement site on the occurrence of CD was not statistically significant; there was no significant correlation between CD and the occurrence of HCRI. 4, The positive bacterial culture rate of HCRI was low (23.8%); the treatment was based on the combined drug mode of systemic intravenous application of antibiotics, supplemented by in situ tube replacement and extubation, in which the extubation rate of catheter-associated bacteremia (CRB) combined with or without other forms of infection was high. 5, In CD treatment, thrombolysis, catheter arteriovenous end interchange and repositioning, and extubation were 16 (32.7%), 12 (24.5%), and 12 (24.5%) cases, respectively. 6. In deep vein obstruction syndrome, the incidence of subclavian and internal jugular vein placement was 11 (5.5%) and 2 (4.7%), respectively, with no significant difference. Conclusion: 1. Placement site, retention time, advanced age, and diabetes mellitus are important risk factors for the occurrence of HCRI. 2. The placement site was associated with the occurrence of HCRI, with a low incidence of HCRI in subclavian vein placement and a high incidence of HCRI in femoral vein placement; the internal jugular vein is still preferred. 3. The duration of placement has an effect on the incidence of HCRI and CD, and the incidence of both is significantly higher in patients who have been placed for more than 2 weeks. 4. The combined drug mode based on systemic intravenous application of antibiotics is the first choice for HCRI treatment, but specific antibiotics should be selected in time according to the results of bacterial culture and drug sensitivity test. 5.The treatment of CD is mainly thrombolytic therapy supplemented by catheter arteriovenous end interchange. 6.Be alert to the occurrence of dialysis catheter-associated obstruction syndrome.